Summary
We report the case of a 26-year-old man in whom glioblastoma multiforme had recurred six months following a subtotal resection. Despite radiotherapy and a course of interferon beta and ACNU, the tumour increased in size (to 3 cm) and there was neurological deterioration. Treatment was then initiated with LAK cells, together with ACNU and interferon beta. After three courses of LAK cells, tumour size was markedly reduced, and at about six months the tumour had nearly disappeared on computed tomographic (CT) scans. At one year, and after nine courses of LAK cell therapy (total dose of 2.7×109 cells) infused via an Ommaya reservoir and supplemented by ACNU and interferon beta, the tumour has disappeared and the patient is considered to be in complete remission since 6 months. This marked response is thought to be due chiefly to LAK cell therapy. The relatively low dose administered was well-tolerated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bosnes V, Hirschberg H (1988) Comparison of in vitro glioma cell cytoxicity of LAK cells from glioma patients and healthy subjects. J Neurosurg 69: 234–238
George RE, Loudon WG, Moser RPet at (1988) In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg 69: 403–409
Grimm EA, Mazumder A, Zhang HZet al (1982) Lymphokineactivated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841
Grimm EA, Ramsey KM, Mazumder Aet al (1983) Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157: 884–897
Iizuka H, Naganuma H, Yabusaki Nel al (1988) Study on lymphokine activated killer (LAK) cells. I. Improved LAK cell induction in vitro. Yamanashi Med J 3: 97–103
Jacobs SK, Wilson DJ, Kornblith PLet al (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res 46: 2101–2104
Jacobs SK, Wilson DJ, Kornblith PLet al (1986) In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64: 114–117
Jacobs SK, Wison DJ, Kornblith PLet al (1986) Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64: 743–749
Jacobs SK, Wilson DJ, Melin Get al (1986) Interleukin-2 and lymphokine-activated killer (LAK) cells in the treatment of malignant glioma: Clinical and experimental studies. Neurol Res 8: 81–87
Okamoto Y, Shimizu K, Tamura Ket al (1988) An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 94: 47–52
Rosenberg SA, Lotze MT, Muul LMet al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313: 1485–1492
Rosenberg SA, Lotze MT, Muul LMet al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose IL-2. N Eng J Med 316: 889–897
Shimizu K, Okamoto Y, Miyao Yet al (1987) Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 66: 519–521
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Naganuma, H., Kimurat, R., Sasaki, A. et al. Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Acta neurochir 99, 157–160 (1989). https://doi.org/10.1007/BF01402326
Issue Date:
DOI: https://doi.org/10.1007/BF01402326